T-lineage acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic cancer in which novel more effective antileukemic drugs are needed for the treatment of patients with chemotherapy resistant disease. We recently found that aberrant activation of the NOTCH signaling pathway plays a critical role in the pathogenesis of more than 50% of human T-cell lymphoblastic leukemias (T-ALL), in which activating mutations in NOTCH1 result in constitutive NOTCH signaling. Thus, inhibition of NOTCH 1 signaling using y-secretase inhibitors (GSIs) to block a critical activation-associated proteolytic cleavage of the NOTCH1 receptor is emerging as a promising novel strategy for the treatment of T-ALL. Our central hypothesis is that the aberrant activation of NOTCH1 regulates critical downstream target genes which contribute to cell transformation in T-ALL. The goals of this research are to identify specific pathogenic target genes, transcriptional programs and molecular mechanisms that lie downstream of oncogenic NOTCH1, and assess their contribution to the transformation of T-cell progenitors. Ultimately, we will exploit these results to develop effective, highly specific therapies based on molecularly targeted antileukemic agents. To achieve these objectives, we propose the following specific aims:
Aim 1. To define the structure of the transcriptional programs activated by NOTCH1 in T-ALL. In this aim, we will use a combination of gene expression arrays and ChlP-on-chip analysis to define the structure of the transcriptional network activated by aberrant NOTCH1 signaling.
Aim 2. To clarify the specific leukemogenic mechanisms by which aberrant activation of NOTCH1 signaling in T-cell progenitors results in dysregulated proliferation and survival.
This specific aim i s based on the hypothesis that the transcriptional program activated by the constitutive NOTCH1 signaling contributes to the pathogenesis of T-ALL through the disordered regulation of cell proliferation and apoptosis in the context of T-cell development. Thus, we will define the specific roles and the mechanisms through which each of these pathways contributes to the pathogenesis of NOTCH- induced thymic malignancies. To achieve this goal we will block NOTCH1 signaling at strategic points in T-ALL cells and determine the mechanisms that mediate the effects and of inactivation of this oncogene in: (i) cell cycle progression, (ii) induction of apoptosis and (iii) tumorigenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA120196-04
Application #
7741243
Study Section
Special Emphasis Panel (ZRG1-ONC-U (90))
Program Officer
Mccarthy, Susan A
Project Start
2006-12-01
Project End
2011-11-30
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
4
Fiscal Year
2010
Total Cost
$305,900
Indirect Cost
Name
Columbia University (N.Y.)
Department
Pediatrics
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Sanchez-Martin, Marta; Ambesi-Impiombato, Alberto; Qin, Yue et al. (2017) Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proc Natl Acad Sci U S A 114:2006-2011
Schnell, Stephanie A; Ambesi-Impiombato, Alberto; Sanchez-Martin, Marta et al. (2015) Therapeutic targeting of HES1 transcriptional programs in T-ALL. Blood 125:2806-14
Belver, Laura; Ferrando, Adolfo A (2015) Aberrant cytokine production by nonmalignant cells in the pathogenesis of myeloproliferative tumors and response to JAK inhibitor therapies. Cancer Discov 5:234-6
Herranz, Daniel; Ambesi-Impiombato, Alberto; Sudderth, Jessica et al. (2015) Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nat Med 21:1182-9
Ntziachristos, Panagiotis; Tsirigos, Aristotelis; Welstead, G Grant et al. (2014) Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 514:513-7
Herranz, Daniel; Ambesi-Impiombato, Alberto; Palomero, Teresa et al. (2014) A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat Med 20:1130-7
Piovan, Erich; Yu, Jiyang; Tosello, Valeria et al. (2013) Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 24:766-76
Van Vlierberghe, Pieter; Ambesi-Impiombato, Alberto; De Keersmaecker, Kim et al. (2013) Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood 122:74-82
Wong, Gladys W; Knowles, Gisele C; Mak, Tak W et al. (2012) HES1 opposes a PTEN-dependent check on survival, differentiation, and proliferation of TCRýý-selected mouse thymocytes. Blood 120:1439-48
Haydu, J Erika; De Keersmaecker, Kim; Duff, Mary Kaye et al. (2012) An activating intragenic deletion in NOTCH1 in human T-ALL. Blood 119:5211-4

Showing the most recent 10 out of 43 publications